Welcome to our dedicated page for Xortx Therapeutics SEC filings (Ticker: XRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The XORTX Therapeutics Inc. (XRTX) SEC filings page provides access to the company’s U.S. regulatory disclosures as a foreign private issuer. XORTX files annual reports on Form 20-F and current reports on Form 6-K under the Securities Exchange Act of 1934. These filings furnish investors with information on financial performance, clinical and regulatory progress, securities offerings, and material corporate developments related to the company’s gout and kidney disease programs.
Recent Form 6-K submissions have included condensed interim consolidated financial statements, management discussion and analysis, and officer certifications, as well as press releases describing registered direct offerings, private placements, Nasdaq minimum bid price notifications, and the binding term sheet to acquire the VB4-P5 renal anti-fibrotic program from Vectus Biosystems Limited. Certain 6-K exhibits, such as legal opinions on the validity of securities, are incorporated by reference into XORTX’s shelf registration statement on Form F-3 (File No. 333-269429).
Through this page, users can review key filing types relevant to XORTX’s sector, including 6-K reports detailing clinical and regulatory updates for the XRx-026 gout program and related XORLO™ formulation, as well as financing structures involving common shares, pre-funded warrants, and agent warrants. The filings also document the company’s responses to Nasdaq listing requirements and its use of at-the-market and registered offerings to fund development of gout, ADPKD, acute kidney injury, and diabetic nephropathy programs.
Stock Titan enhances these filings with AI-powered summaries that explain the significance of each document in clear language. Real-time updates from EDGAR, along with structured access to XORTX’s 6-K reports and other registered offerings, help investors quickly understand how regulatory events, financings, and clinical disclosures affect the company’s xanthine oxidase–targeted pipeline.
XORTX Therapeutics Inc., a clinical-stage biotechnology company based in Canada and listed on Nasdaq, filed its annual report for the year ended December 31, 2025. The company focuses on kidney and metabolic diseases using small-molecule drugs.
XORTX reported net losses of US$2,158,065 in 2023, US$3,313,346 in 2024 and US$2,656,304 in 2025, with an accumulated deficit of about US$23,824,557 as of December 31, 2025. It has no approved products and has not generated revenue from product sales.
The lead program, XRx-026 for gout, is the most advanced; XRx-008 for ADPKD holds U.S. Orphan Drug Designation, and XRx-101 targets acute kidney injury linked to respiratory virus infections. Management warns it expects continued losses, needs substantial additional funding, faces significant clinical, regulatory and commercialization risks, and could experience share price volatility with potential dilution for shareholders.
XORTX Therapeutics Inc. has proposed three new director nominees for election at its March 24, 2026 annual and special shareholder meeting. George Scorsis, Richard Grieve and Mika Grasso will stand for election in place of three current nominees.
The change is tied to a significant financing initiative, which requires these new directors to join the board as a condition of closing and remains subject to TSX Venture Exchange approval. If the financing is not completed, the new directors will resign and the resulting vacancies will be filled later by the company.
Management proxies will be voted in favour of the new nominees unless shareholders withhold votes. The board unanimously recommends voting for all resolutions, while XORTX continues advancing late-stage programs targeting gout and progressive kidney disease.
XORTX Therapeutics Inc. filed a Form 6-K highlighting that independent proxy advisory firms, including Institutional Shareholder Services (ISS), have recommended that shareholders vote “FOR” the proposed share consolidation at the upcoming shareholder meeting on March 24, 2026. The company’s board of directors unanimously recommends that shareholders vote for all resolutions.
The proxy voting deadline is March 20, 2026, and shareholders of record as of the close of business on February 20, 2026 are eligible to vote. Laurel Hill Advisory Group has been engaged to provide voting assistance. XORTX also reiterates its late-stage clinical pipeline in gout, ADPKD, acute kidney injury and diabetic nephropathy.
XORTX Therapeutics Inc. filed a Form 6-K to notify shareholders that meeting materials for its upcoming Annual and Special Meeting are now available and have been mailed. The meeting will be held on March 24, 2026 at 10:00 a.m. Calgary time at the company’s Calgary offices.
Shareholders of record as of February 20, 2026 will vote on fixing the board at five directors, electing directors, appointing the auditor and authorizing its remuneration, confirming and approving the stock option plan, and an ordinary resolution to amend the articles to allow a consolidation of the common shares on the basis of up to five pre-consolidation shares for one post-consolidation share. The board unanimously recommends voting for all items, and proxy voting closes on March 20, 2026.
XORTX Therapeutics Inc. is calling an annual and special shareholder meeting on March 24, 2026 to vote on several key corporate items. Shareholders will elect five directors, reappoint Davidson & Company LLP as auditor, and re-approve a rolling stock option plan reserving up to 10% of outstanding common shares for equity incentives.
The company is also asking shareholders to authorize a share consolidation of up to five pre‑consolidation shares for one post‑consolidation share. This flexibility is intended to help XORTX regain compliance with Nasdaq’s US$1.00 minimum bid price requirement before an April 13, 2026 deadline, after which its shares risk delisting if compliance is not restored. As of February 20, 2026, XORTX had 6,962,218 common shares outstanding.
XORTX Therapeutics filed its 2025 audited financial statements and MD&A, showing a net loss of $2,656,304 and negative operating cash flow of $2,768,723. Cash fell to $864,514 at December 31, 2025, with an accumulated deficit of $23,824,557 and shareholders’ equity of $2,084,459.
The auditors and management highlight a material uncertainty that casts significant doubt on XORTX’s ability to continue as a going concern because it must secure additional financing to fund research, clinical trials and operations. In 2025 the company raised equity, issued and exercised pre‑funded warrants, and expanded its warrant structure to fund activities.
XORTX signed a binding term sheet to acquire the VB4‑P5 renal anti‑fibrotic program from Vectus Biosystems for $3,000,000 in shares and recorded $293,803 of deferred acquisition costs. The company also discloses a Nasdaq notice of non‑compliance with minimum bid price rules while working to regain compliance.
XORTX Therapeutics Inc. has filed Amendment No. 1 to a Form F-1 to register a primary offering of up to 12,500,000 common shares, 12,500,000 pre-funded warrants, 12,500,000 common warrants and 25,000,000 common shares issuable upon warrant exercises. The securities are offered on a reasonable best efforts basis at an assumed price of $0.40 per share, the recent Nasdaq closing price. Each share or pre-funded warrant is sold together with one common warrant, which will be exercisable for three years at a price no lower than the latest TSXV closing price. XORTX estimates net proceeds of about $4.3 million, intended mainly to fund research and development, working capital and general corporate purposes. The company highlights its late-stage gout program XRx-026, ADPKD program XRx-008, and additional kidney and metabolic disease candidates, while cautioning that investing in the securities involves a high degree of risk and potential dilution.
XORTX Therapeutics Inc. filed a Form 6-K highlighting more time to close its planned acquisition of Vectus Biosystems’ Renal Anti-Fibrotic Therapeutic Program, including the novel compound VB4-P5. An amendment now targets closing on or before March 31, 2026 to complete intellectual property transfer and final documentation.
The company also scheduled its Annual and Special Meeting of Shareholders for March 24, 2026, with shareholders of record on February 20, 2026 eligible to vote. In connection with appointing Krysta Davies Foss to the board, XORTX granted 20,000 stock options at an exercise price of CAD $0.69 for five years.
XORTX Therapeutics Inc. filed a Form 6-K. The filing incorporates Exhibits 99.2 and 99.3 by reference into the company’s Registration Statement on Form F-3 (File No. 333-269429), adding legal opinions regarding the legality of securities being registered from Dentons Canada LLP and Troutman Pepper Locke LLP.
The exhibit index also lists a press release dated October 29, 2025 (Exhibit 99.1). The report is signed by President and Chief Executive Officer Allen Davidoff on October 31, 2025. This is an administrative update linking legal opinions to the existing F-3 shelf.